Cases

Generative AI tools are now being used by fashion designers to create textile prints inspired by Indigenous, African, or Asian cultural motifs—often without direct collaboration with source communities. In 2024, brands like H&M and Zara faced backlash for AI-generated 'ethnic prints' that closely resembled sacred Maasai beadwork or Andean weaving symbols. While AI can accelerate design, it risks decontextualizing and commodifying culturally significant patterns that carry spiritual, social, or historical meaning. UNESCO's 2023 guidelines on AI and cultural heritage emphasize the need for consent and benefit-sharing, but enforcement in fashion remains weak. Some designers argue AI 'remixes' are transformative art; others say they perpetuate extractive practices. Should AI-generated fashion patterns that resemble protected cultural heritage require prior informed consent from originating communities?

In 2025, institutions like the Rijksmuseum and the Louvre are piloting AI systems to aid in art restoration—using machine learning to reconstruct damaged areas, identify original pigments via spectral analysis, or simulate aging effects. While these tools can accelerate decision-making and reduce human error, conservators warn against overreliance. A recent controversy involved an AI 'completed' a fragmented Renaissance drawing, but the algorithm filled gaps using stylistic averages rather than historical evidence, potentially distorting the artist's intent. The core tension lies between efficiency and authenticity: should AI generate hypotheses or only assist in analysis? Conservators, art historians, and technologists are divided on whether AI's interpolative nature violates the ethical principle of minimal intervention in conservation practice.

Cadmium-based pigments—known for their vibrant hues, lightfastness, and opacity—have long been staples in professional oil painting. However, growing environmental and health regulations in the EU and California (under Proposition 65) are restricting their sale and use due to toxicity concerns. In 2024, major manufacturers like Winsor & Newton and Gamblin introduced 'cadmium-free' alternatives using azo pigments, claiming comparable performance. Traditionalists argue these substitutes lack the chromatic strength and archival stability of genuine cadmiums, potentially compromising artistic intent and longevity. Meanwhile, material scientists and eco-conscious artists advocate for safer alternatives, citing risks to studio health and environmental impact during pigment production and disposal. The debate affects painters, educators, conservators, and manufacturers, raising questions about balancing artistic integrity with sustainability and safety.

The NFT art market, though cooled since its 2021 peak, continues to influence digital art economics. A key innovation was the automatic resale royalty—typically 5–10%—coded into NFT smart contracts, ensuring artists benefit from secondary market appreciation. However, in 2024, major platforms like OpenSea and Blur removed mandatory royalty enforcement, shifting to optional or honor-based systems. This has slashed royalty income for many digital creators. Artists argue that resale rights are essential for sustainable careers in a volatile market, while collectors and traders claim mandatory royalties reduce liquidity and platform competitiveness. The debate touches on fairness, market efficiency, and whether blockchain should enforce ethical norms. For the digital art community, this is a pivotal moment in defining creator rights in decentralized markets.

As AI image generators like Midjourney and Stable Diffusion become accessible to artists, public arts councils worldwide are confronting a policy dilemma: should AI-assisted or AI-generated works be eligible for public funding? In early 2025, the Canada Council for the Arts updated its guidelines to require disclosure of AI use and restrict funding to works where 'human authorship is predominant.' Similar debates are unfolding in the EU and Australia. Proponents of inclusion argue that AI is merely a new tool—like photography once was—and that gatekeeping stifles innovation. Critics contend that public grants should support human labor, skill development, and cultural expression, not outputs derived from unlicensed training data. The issue intersects with intellectual property, labor ethics, and the definition of artistic authorship. For public funding bodies, the stakes involve maintaining fairness, encouraging innovation, and upholding cultural values.

In 2024–2025, numerous museums—including the Brooklyn Museum and the San Francisco Museum of Modern Art—have faced mounting pressure to modernize their conservation and archival practices, particularly for time-based and digital media art. These works, often created with obsolete software or hardware, require specialized storage, emulation, and migration strategies that traditional conservation budgets rarely cover. Some institutions are exploring deaccessioning—selling works from their permanent collections—to fund these efforts, a practice historically restricted by ethical codes (e.g., AAMD guidelines) to acquisitions only. However, amid climate risks, technological obsolescence, and declining public funding, curators and conservators are re-evaluating whether ethical frameworks should evolve. Stakeholders include museum directors, conservators, artists, donors, and the public. The decision impacts not only institutional integrity but also the survival of digital and contemporary artworks that define 21st-century artistic practice.

Psilocybin and MDMA-assisted therapies have shown remarkable promise in clinical trials for treatment-resistant depression (TRD) and PTSD, with effects lasting months after just 1–2 sessions. In 2023, Australia became the first country to allow prescription of psilocybin for TRD, and the FDA is reviewing MDMA for PTSD (decision expected 2024). However, these therapies require intensive psychotherapy support, controlled settings, and are not yet scalable. Traditional antidepressants like SSRIs, while less effective for TRD, are widely accessible and familiar. The question is whether psychedelics should move beyond last-resort status to become a primary option for TRD, given their efficacy, or remain restricted due to logistical, safety, and equity concerns.

Antibiotic use disrupts the gut microbiome, leading to diarrhea in up to 30% of patients and Clostridioides difficile infection in 5%. Probiotics—especially Lactobacillus rhamnosus GG and Saccharomyces boulardii—have been promoted to prevent this. However, a 2023 Cochrane review of 114 studies found mixed evidence: some strains show modest benefit, but others show no effect or even potential harm in immunocompromised patients. The American Gastroenterological Association now recommends against routine probiotic use during antibiotics, citing insufficient evidence and risk of fungemia or bacteremia in vulnerable populations. Yet many clinicians and patients continue using them based on historical practice and anecdotal success. This trial examines whether the potential benefits outweigh the risks and costs in average-risk adults.

Melatonin, widely used for sleep onset and jet lag, is sold over-the-counter in the U.S. as a dietary supplement under the 1994 DSHEA law, meaning it bypasses FDA pre-market safety and efficacy review. Recent studies reveal significant inconsistencies: some products contain 83–478% of labeled melatonin, and some include unlisted serotonin, posing health risks. While generally safe for short-term use, long-term effects—especially in children—are poorly studied. The American Academy of Pediatrics has warned against routine use in kids. Meanwhile, in the EU and Canada, melatonin is regulated as a prescription or pharmacy-only drug. With sleep disorders on the rise and melatonin sales exceeding $1 billion annually, calls are growing for reclassification to ensure purity, dosing accuracy, and appropriate use guidance.

In 2021, the U.S. Preventive Services Task Force (USPSTF) lowered the recommended age for colorectal cancer screening from 50 to 45 due to rising incidence in younger adults. While colonoscopy remains the gold standard, non-invasive options like the multi-target stool DNA test (Cologuard) and fecal immunochemical tests (FIT) are gaining popularity. Recent data shows Cologuard detects 92% of colorectal cancers but has a high false-positive rate (13%), leading to unnecessary colonoscopies. Meanwhile, colonoscopy carries risks (perforation, sedation complications) and access barriers. Newer blood-based and microbiome-based screening tools are in development. The dilemma: should average-risk individuals start with at-home tests and reserve colonoscopy for positives, or is early colonoscopy still justified for its therapeutic and diagnostic superiority?